Efficacy of ranolazine for rhythm control in an elderly patient with paroxysmal atrial fibrillation.
We report the case of an elderly woman with coronary heart disease and paroxysmal atrial fibrillation. It could be hypothesized that the predisposing anatomic substrate for arrhythmogenesis in this patient derived from both age-related left atrial dilation and coexistent ischaemic heart disease. Unfortunately the usual antiarrhythmic therapy was unsafe or not feasible for this subject. Ranolazine 750 mg twice daily completely suppressed atrial fibrillation recurrences.
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
E
E
Santillo
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
M
M
Migale
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
D
D
Postacchini
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
L
L
Fallavollita
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
L
L
Marini
Geriatrics-Rehabilitative Department, Italian National Research Center on Aging (I.N.R.C.A.), Fermo, Italy.
F
F
Balestrini
D000083:Acetanilides / Q000627:therapeutic use*; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D000069458:Ranolazine; D016896:Treatment Outcome
D000083:Acetanilides; D010879:Piperazines; D000069458:Ranolazine